Byondis
Myrthe Rouwette is a Senior Scientist in Bioanalysis & Protein Interaction at Byondis since April 2020, specializing in assay development for bioanalysis and protein interaction studies, particularly for antibody-drug conjugates. Responsibilities include developing PK and immunogenicity assays, transferring these assays to contract research organizations (CROs), and providing scientific support for assay validation. Prior experience includes roles as a Scientist at Synthon and as a PhD student at Hasselt University, where the focus was on identifying novel (auto)antibody targets for Clinically Isolated Syndrome and Multiple Sclerosis, along with educational responsibilities. Myrthe holds a Master of Science and a Bachelor of Science in Medical Biology from Radboud University.
This person is not in the org chart
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.